FOLH1 and neoplasm: As the initial results highlighted the added clinical value of prostate-specific-antigen (PSMA)-targeted positron emission tomography (PET) imaging in metastatic RCC due to the PSMA-expression of tumor neovascularization [1,2,3,4,5], this patient underwent 18F-PSMA-1007 PET/CT for whole body staging before any further tumor-specific therapies.